Bioanalysis Zone, the knowledge hub for the bioanalysis industry, has named Matthew Lockett the winner of the 2017 New Investigator Award, a prestigious recognition of the most promising early-career researchers in the bioanalytical field. The New Investigator Award is awarded annually by Bioanalysis Zone and Bioanalysis, a MEDLINE-indexed journal covering the latest scientific, technical and regulatory developments relevant to bioanalysts. Both the online community and the journal are powered by Future Science Group.
This year’s winner, Matthew, was nominated by Jeff Johnson (University of North Carolina at Chapel Hill; NC, USA) in recognition of his work on developing 3D tissue and tumor models to study the role of oxygen in promoting drug resistance. On receiving the award, Matthew commented: “I am truly humbled to have been selected as this year’s Bioanalysis Zone New Investigator Award winner. This award is the result of strong support from mentors and colleagues. It is also the result of the continued support of the talented students in my lab, whose innovation and drive are pushing our research in a host of new and exciting directions! I see this reward as an encouragement to keep on our research path, the fuel needed as we continue to tackle tough problems.” As the winner of the New Investigator Award, Matthew will present his work at the European Bioanalysis Forum (EBF) Open Symposium, in Barcelona, Spain on 15 November 2017. He also receives a one-year subscription to Bioanalysis and US $1000 courtesy of award sponsors Waters Corporation (MA, USA), a provider of laboratory solutions and software in separations science, mass spectrometry and thermal analysis.
Erin Chambers, Director in Scientific Operations and Principal Applications Chemist (Waters Corporation) served as a judge for the Bioanalysis Zone New Investigator Award: “I’m really proud to be part of the New Investigator Award. The industry needs to do more of this. We need to continue to recognize people early in their career, while shining a spotlight on great science no matter where people are in their career: early, mid, or late. There’s a lot of other great work out there that’s not getting recognized in the way it can or should.” Naamah Maundrell, Editor of Bioanalysis Zone, added: “It’s been delightful coordinating this year’s award, working with hugely talented bioanalysts from all over the world. I would like to congratulate Matthew and all of this year’s nominees for their inspiring research and contribution to the bioanalytical field.”
Matthew won the public vote after four finalists were shortlisted by the judges. The finalists included, Swarnapali De Silva Indrasekara (Duke University; NC, USA), Michael Witting (Helmholtz Zentrum Munchen; Munich, Germany) and Yu Shrike Zhang (Harvard Medical School; MA, USA), who was awarded a special recognition from the judges after a tight competition.
A video introducing Matthew is available to view at http://www.bioanalysis-zone.com
Nominations are now being accepted for the 2018 New Investigator Award, here. Alternatively, contact the Editor Naamah Maundrell directly ([email protected]). Further details on the 10th EBF Open Symposium can be found here.
About Bioanalysis Zone
Since launching in 2011, Bioanalysis Zone has attracted over 9,000 active members from the global bioanalytical community, representing the pharmaceutical, biotech and CRO industries, along with academia and healthcare. Each month, thousands of members visit the site to read industry news, peer-reviewed research, exclusive interviews, webinars and commentaries. Join the Bioanalysis Zone Twitter and LinkedIn group for updates.
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG’s portfolio includes two imprints: Future Science and Future Medicine. Both publish eBooks and journals. In addition to this core publishing business FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.future-science-group.com.